Articles from USAntibiotics

USAntibiotics, the only U.S. manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Mark Tengler to the position of senior vice president of manufacturing technologies. A seasoned pharmaceutical leader with more than three decades of expertise, Tengler will oversee all aspects of manufacturing at the company’s world-class 394,000-square-foot facility, including antibiotics processing and packaging, plastics processing, engineering, maintenance, building services and warehouse management.

USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs. In this role, Wesoloski leads all aspects of quality assurance and control, compliance, regulatory affairs and pharmacovigilance related to the manufacturing, packaging, distribution and post-marketing requirements for the company’s antibiotics.

USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Steven Lutz to vice president of strategic accounts. In this role, Lutz oversees the organization’s commercial strategy to drive continued growth and market share in alignment with the company’s business objectives.

USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxicillin Clavulanate, the popular antibiotics commonly known as Amoxil® and Augmentin®, released the following statement ahead of the U.S. House Energy and Commerce Committee Subcommittee on Oversight and Investigations hearing titled “Examining The Root Causes Of Drug Shortages: Challenges In Pharmaceutical Drug Supply Chains.”